HSDT Stock — Helius Medical Technologies, Inc.

Helius Medical Technologies, Inc. (HSDT)

Updated October 16, 2026.

HSDT is a Stock. Total return is -100.0% over the past 12.3 years, 477.9 points behind SPY at 377.9%.

Helius Medical Technologies operates as a digital asset treasury on the Solana blockchain while developing neuromodulation medical devices, specifically a non-implantable stimulator that delivers electrical stimulation to treat gait and balance deficits. The company does not currently distribute dividends to shareholders. This security appeals primarily to investors seeking exposure to early-stage healthcare technology and blockchain-based business models rather than those focused on income generation.

HSDT performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 12.3 years, 477.9 points behind SPY at 377.9%. Over the past year its total return — price change plus distributions reinvested — is -77.8%. Its deepest 1-year drawdown was 87.4%.

HSDT key facts

Asset type

Stock

Asset class

Equity

Inception date

06/27/2014

Distribution frequency

None

Last close

$2.24 (as of 2026-10-16)

Market cap

$145,834,246

Average volume

445205.0

Payment date

01/04/2021

Beta

1.116

Payout ratio

0.0%

P/E ratio

0.04

EPS

$50.65

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

HSDT risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 87.4%.

Who may consider HSDT — and who may not

It is a weaker fit for investors who need monthly cash flow (HSDT does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on HSDT

• All tickers starting with H

Tagged: Healthcare, Small Caps.

Frequently asked questions